Mendus

.Hero-module--bg-image--629a6.gbi-1301260899-r7vdGYqbaBfWZuXoEU6hWf:before { opacity: 1; background-image: url('/static/6d9b87783341ce51e45ef11f598677aa/6f033/Investors_1-scaled.jpg'); }

Changing the course of cancer treatmentWe explore the power of the immune system to improve long-term survival of cancer patients, while preserving health and quality of life.
About us
<picture><source type="image/webp" srcSet="/static/48407146a7282fec8f811ea39c36c80e/5cf40/251002--e1759385142797.webp 147w,/static/48407146a7282fec8f811ea39c36c80e/1bee1/251002--e1759385142797.webp 294w,/static/48407146a7282fec8f811ea39c36c80e/b7b1b/251002--e1759385142797.webp 588w" sizes="(min-width: 588px) 588px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 588px) 588px, 100vw" decoding="async" loading="lazy" src="/static/48407146a7282fec8f811ea39c36c80e/c5078/251002--e1759385142797.png" srcSet="/static/48407146a7282fec8f811ea39c36c80e/df79c/251002--e1759385142797.png 147w,/static/48407146a7282fec8f811ea39c36c80e/cf5d1/251002--e1759385142797.png 294w,/static/48407146a7282fec8f811ea39c36c80e/c5078/251002--e1759385142797.png 588w" alt=""/></picture>
Press Release More details
Interview
<picture><source type="image/webp" srcSet="/static/3bf5d9a2043ea12a69d4fe6cc8971382/c690a/251121-BTG-3.webp 529w,/static/3bf5d9a2043ea12a69d4fe6cc8971382/7f271/251121-BTG-3.webp 1058w,/static/3bf5d9a2043ea12a69d4fe6cc8971382/1404b/251121-BTG-3.webp 2116w" sizes="(min-width: 2116px) 2116px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 2116px) 2116px, 100vw" decoding="async" loading="lazy" src="/static/3bf5d9a2043ea12a69d4fe6cc8971382/4ea1d/251121-BTG-3.jpg" srcSet="/static/3bf5d9a2043ea12a69d4fe6cc8971382/8abc6/251121-BTG-3.jpg 529w,/static/3bf5d9a2043ea12a69d4fe6cc8971382/25568/251121-BTG-3.jpg 1058w,/static/3bf5d9a2043ea12a69d4fe6cc8971382/4ea1d/251121-BTG-3.jpg 2116w" alt=""/></picture>
Spotlight from Q3 2025 report:  Bjørn-Tore GjertsenRead the full interview
<picture><source type="image/webp" srcSet="/static/43e6a434bd23560bea0b5d842e2f5f18/97812/251119-directed-share-issue-ENG-e1763544013831.webp 190w,/static/43e6a434bd23560bea0b5d842e2f5f18/5fee8/251119-directed-share-issue-ENG-e1763544013831.webp 381w,/static/43e6a434bd23560bea0b5d842e2f5f18/be433/251119-directed-share-issue-ENG-e1763544013831.webp 761w" sizes="(min-width: 761px) 761px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 761px) 761px, 100vw" decoding="async" loading="lazy" src="/static/43e6a434bd23560bea0b5d842e2f5f18/bb657/251119-directed-share-issue-ENG-e1763544013831.jpg" srcSet="/static/43e6a434bd23560bea0b5d842e2f5f18/e80ec/251119-directed-share-issue-ENG-e1763544013831.jpg 190w,/static/43e6a434bd23560bea0b5d842e2f5f18/8a56b/251119-directed-share-issue-ENG-e1763544013831.jpg 381w,/static/43e6a434bd23560bea0b5d842e2f5f18/bb657/251119-directed-share-issue-ENG-e1763544013831.jpg 761w" alt=""/></picture>
 More details 
<picture><source type="image/webp" srcSet="/static/8c4bd10248aa4638e1e058268f071cd9/8d52a/251113-Q32025-ENG-e1763019008676.webp 234w,/static/8c4bd10248aa4638e1e058268f071cd9/39934/251113-Q32025-ENG-e1763019008676.webp 467w,/static/8c4bd10248aa4638e1e058268f071cd9/be438/251113-Q32025-ENG-e1763019008676.webp 934w" sizes="(min-width: 934px) 934px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 934px) 934px, 100vw" decoding="async" loading="lazy" src="/static/8c4bd10248aa4638e1e058268f071cd9/05bb7/251113-Q32025-ENG-e1763019008676.jpg" srcSet="/static/8c4bd10248aa4638e1e058268f071cd9/5f079/251113-Q32025-ENG-e1763019008676.jpg 234w,/static/8c4bd10248aa4638e1e058268f071cd9/0fb3c/251113-Q32025-ENG-e1763019008676.jpg 467w,/static/8c4bd10248aa4638e1e058268f071cd9/05bb7/251113-Q32025-ENG-e1763019008676.jpg 934w" alt=""/></picture>
Mendus publishes Q3 reportMore details 
CEO comment
<picture><source type="image/webp" srcSet="/static/292a97e4402d8b7973a59f062391483f/f0111/Manting_banner_headspace-scaled-e1746523332415.webp 428w,/static/292a97e4402d8b7973a59f062391483f/6e776/Manting_banner_headspace-scaled-e1746523332415.webp 855w,/static/292a97e4402d8b7973a59f062391483f/bd09f/Manting_banner_headspace-scaled-e1746523332415.webp 1710w" sizes="(min-width: 1710px) 1710px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 1710px) 1710px, 100vw" decoding="async" loading="lazy" src="/static/292a97e4402d8b7973a59f062391483f/a1257/Manting_banner_headspace-scaled-e1746523332415.jpg" srcSet="/static/292a97e4402d8b7973a59f062391483f/11168/Manting_banner_headspace-scaled-e1746523332415.jpg 428w,/static/292a97e4402d8b7973a59f062391483f/e5cca/Manting_banner_headspace-scaled-e1746523332415.jpg 855w,/static/292a97e4402d8b7973a59f062391483f/a1257/Manting_banner_headspace-scaled-e1746523332415.jpg 1710w" alt=""/></picture>
Updated clinical development strategy based on positive dataMore details 
<picture><source type="image/webp" srcSet="/static/48407146a7282fec8f811ea39c36c80e/5cf40/251002--e1759385142797.webp 147w,/static/48407146a7282fec8f811ea39c36c80e/1bee1/251002--e1759385142797.webp 294w,/static/48407146a7282fec8f811ea39c36c80e/b7b1b/251002--e1759385142797.webp 588w" sizes="(min-width: 588px) 588px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 588px) 588px, 100vw" decoding="async" loading="lazy" src="/static/48407146a7282fec8f811ea39c36c80e/c5078/251002--e1759385142797.png" srcSet="/static/48407146a7282fec8f811ea39c36c80e/df79c/251002--e1759385142797.png 147w,/static/48407146a7282fec8f811ea39c36c80e/cf5d1/251002--e1759385142797.png 294w,/static/48407146a7282fec8f811ea39c36c80e/c5078/251002--e1759385142797.png 588w" alt=""/></picture>
Press Release More details
Interview
<picture><source type="image/webp" srcSet="/static/3bf5d9a2043ea12a69d4fe6cc8971382/c690a/251121-BTG-3.webp 529w,/static/3bf5d9a2043ea12a69d4fe6cc8971382/7f271/251121-BTG-3.webp 1058w,/static/3bf5d9a2043ea12a69d4fe6cc8971382/1404b/251121-BTG-3.webp 2116w" sizes="(min-width: 2116px) 2116px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 2116px) 2116px, 100vw" decoding="async" loading="lazy" src="/static/3bf5d9a2043ea12a69d4fe6cc8971382/4ea1d/251121-BTG-3.jpg" srcSet="/static/3bf5d9a2043ea12a69d4fe6cc8971382/8abc6/251121-BTG-3.jpg 529w,/static/3bf5d9a2043ea12a69d4fe6cc8971382/25568/251121-BTG-3.jpg 1058w,/static/3bf5d9a2043ea12a69d4fe6cc8971382/4ea1d/251121-BTG-3.jpg 2116w" alt=""/></picture>
Spotlight from Q3 2025 report:  Bjørn-Tore GjertsenRead the full interview

<picture><source type="image/webp" srcSet="/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/d7070/Startpage_1-NEW-1.webp 240w,/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/4ce17/Startpage_1-NEW-1.webp 480w,/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/95cd0/Startpage_1-NEW-1.webp 960w" sizes="(min-width: 960px) 960px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 960px) 960px, 100vw" decoding="async" loading="lazy" src="/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/49439/Startpage_1-NEW-1.jpg" srcSet="/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/ff13b/Startpage_1-NEW-1.jpg 240w,/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/28e6b/Startpage_1-NEW-1.jpg 480w,/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/49439/Startpage_1-NEW-1.jpg 960w" alt=""/></picture>
Gaining the 
upper handToday, tumor recurrence is the main cause of cancer-related deaths. We aim to reduce tumor recurrence by harnessing the immune system to act against residual cancer cells.
What we do

<picture><source type="image/webp" srcSet="/static/bfd9bafcd3660b03f3b72edb150264f7/ecbb3/Startpage_2.webp 450w,/static/bfd9bafcd3660b03f3b72edb150264f7/10d3d/Startpage_2.webp 900w,/static/bfd9bafcd3660b03f3b72edb150264f7/7d31d/Startpage_2.webp 1800w" sizes="(min-width: 1800px) 1800px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 1800px) 1800px, 100vw" decoding="async" loading="lazy" src="/static/bfd9bafcd3660b03f3b72edb150264f7/b37a5/Startpage_2.jpg" srcSet="/static/bfd9bafcd3660b03f3b72edb150264f7/ea40c/Startpage_2.jpg 450w,/static/bfd9bafcd3660b03f3b72edb150264f7/a3b1e/Startpage_2.jpg 900w,/static/bfd9bafcd3660b03f3b72edb150264f7/b37a5/Startpage_2.jpg 1800w" alt="&lt;p&gt;Two chemistry laboratory researchers, a young man and a young woman working together in a biology, chemistry research laboratory.= in a university. Focus on the laboratory equipment with the personnel in the background. Photographed in horizontal format.&lt;/p&gt;
"/></picture>
New ways to make a differenceWe apply our understanding of dendritic cell biology to design cancer immunotherapies that stimulate active immunity, the only long-lasting form of immunity.
About us

<picture><source type="image/webp" srcSet="/static/0237bef387e76cffaa6681d16a2b59c4/8cdf4/Startpage_3.webp 302w,/static/0237bef387e76cffaa6681d16a2b59c4/39272/Startpage_3.webp 603w,/static/0237bef387e76cffaa6681d16a2b59c4/0d01b/Startpage_3.webp 1206w" sizes="(min-width: 1206px) 1206px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 1206px) 1206px, 100vw" decoding="async" loading="lazy" src="/static/0237bef387e76cffaa6681d16a2b59c4/e579d/Startpage_3.jpg" srcSet="/static/0237bef387e76cffaa6681d16a2b59c4/8f82e/Startpage_3.jpg 302w,/static/0237bef387e76cffaa6681d16a2b59c4/d2caf/Startpage_3.jpg 603w,/static/0237bef387e76cffaa6681d16a2b59c4/e579d/Startpage_3.jpg 1206w" alt="&lt;p&gt;Molecular Structure. Science background. 3D Render&lt;/p&gt;
"/></picture>
Invest in future cancer careMendus is listed on NASDAQ Stockholm under the ticker symbol IMMU. You will find all relevant information on the Mendus share in our Investors section.
Investors

Latest newsNews and Events
No articles found

.FullWidthImage-module--bg-image-mobile--ba5fc.FullWidthImage-module--hide-in-mobile--9cd89.gbi--752554434-uvC2gkQnmg6Ue11NbVvbKh:before { opacity: 1; background-image: url('/static/58920a993c01776af52e6d8a69a7452d/60e72/What-we-do_1-mobile-1.jpg'); }

What we do

Changing the course of cancer treatment

Press Release

Spotlight from Q3 2025 report: Bjørn-Tore Gjertsen

Mendus publishes Q3 report

Updated clinical development strategy based on positive data

Press Release

Spotlight from Q3 2025 report: Bjørn-Tore Gjertsen

Gaining the upper hand

New ways to make a difference

Invest in future cancer care

Latest news

What we do

Gaining the
upper hand